Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksB.p Marsh Regulatory News (BPM)

Share Price Information for B.p Marsh (BPM)

Share Price is delayed by 15 minutes
Get Live Data
687.00    -5.00 (-0.72%)
Bid:
680.00
Ask:
694.00
Spread: 14.00 (2.059%)
Market Cap: £242.09m
BPM Live PriceLast checked at - London Stock Exchange

Intraday B.p Marsh Share Chart

Secondary Share Sale

12 May 2025 15:17

RNS Number : 3181I
Panmure Liberum Capital Limited
12 May 2025
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND THE INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE AN OFFER TO SELL OR ACQUIRE SECURITIES IN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR IN ANY OTHER JURISDICTION.

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED BY THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS 2019 (AS FURTHER AMENDED, VARIED OR SUBSTITUTED FROM TIME TO TIME AS A MATTER OF UK LAW). UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA THE REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

12 May 2025

 

SECONDARY SHARE SALE

 

Further to the secondary placing completed on 9 May 2025 (the "Placing"), PSC UK Pty Ltd (the "Selling Shareholder") announces that it has today completed the sale of a further 1,822,183 ordinary shares in the capital of B.P. Marsh & Partners Plc ("B.P. Marsh") at a price of 630 pence per share, which represents approximately 4.9% of B.P. Marsh's issued share capital (the "Sale"). The Sale was made to one institutional investor following receipt of buying demand for the ordinary shares after the Placing bookbuild process had completed.

Following completion of the Placing and the Sale, the Selling Shareholder will hold 3,626,440 ordinary shares in B.P. Marsh, representing approximately 9.8% of B.P. Marsh's issued share capital.

Panmure Liberum Limited ("Panmure Liberum") is acting for the Selling Shareholder in connection with the Placing and the Sale. To permit the Sale, Panmure Liberum has waived the 60-day lock-up undertaking that was agreed in connection with the Placing (the "Lock-Up").

The remainder of the B.P. Marsh shares held by the Selling Shareholder following the Sale will remain subject to the Lock-Up.

B.P. Marsh will not receive any proceeds from the Placing or the Sale.

 

Enquiries:

Panmure Liberum

Sole Bookrunner to the Selling Shareholder

Nominated Adviser & Joint Corporate Broker to B.P. Marsh

David Watkins / Atholl Tweedie +44 20 3100 2000

 

 

IMPORTANT NOTICE

This announcement is for information purposes only and is directed only at: (a) persons in member states of the European Economic Area ("EEA") who are qualified investors within the meaning of Article 2(e) of regulation (EU) 2017/1129 (the "Prospectus Regulation") ("Qualified Investors") and (b) in the United Kingdom, persons who (i) have professional experience in matters relating to investments who fall within the definition of "Investment Professionals" in Article 19(5) of the Financial Services And Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), or are high net worth companies, unincorporated associations or partnerships or trustees of high value trusts as described in Article 49(2) of the order and (ii) are "Qualified Investors" as defined in prospectus regulation as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 and (c) otherwise, to persons to whom it may otherwise be lawful to communicate it (each a "Relevant Person"). No other person should act or rely on this announcement and persons distributing this announcement must satisfy themselves that it is lawful to do so. Any investment or investment activity to which this announcement relates is available only to relevant persons and will be engaged in only with relevant persons. The announcement does not itself constitute an offer for sale of any securities.

This announcement is not for publication or distribution or release, directly or indirectly, in or into the United States of America (including its territories and possessions, any state of the United States and the District of Columbia), Canada, Australia, Japan, South Africa or any other jurisdiction where such an announcement would be unlawful. The distribution of this announcement may be restricted by law in certain jurisdictions and persons into whose possession this document or other information referred to herein comes should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. No action has been taken that would permit an offering of ordinary shares or possession or distribution of this announcement in any jurisdiction where action for that purpose is required.

The ordinary shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "Securities Act"), or with any securities regulatory authority of any State or other jurisdiction of the United States, and may not be offered, sold, or transferred, directly or indirectly, in or into the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with the securities laws of any State or any other jurisdiction of the United States. Accordingly, the ordinary shares will be offered and sold only (i) outside of the United States in "offshore transactions" to persons who are not "U.S. persons" within the meaning of and pursuant to Regulation S under the Securities Act; and (ii) within the United States only to persons who are reasonably believed to be "qualified institutional buyers" (as defined in Rule 144A under the Securities Act) and who are also "qualified purchasers" (as defined in Section 2(a)(51)(A) of the US Investment Company Act of 1940, as amended) and who have delivered to Panmure Liberum a US Investor Letter substantially in the form provided to it, in each case, pursuant to an exemption from, or in a transaction not subject to, registration under the Securities Act. No public offering of the ordinary shares will be made in the United States or elsewhere.

Neither the Placing nor the Sale has been approved or disapproved by the US Securities and Exchange Commission, any state securities commission in the United States or any US regulatory authority, nor have any of the foregoing authorities passed upon or endorsed the merits of the Placing or the Sale, or the accuracy or adequacy of this announcement. Any representation to the contrary is a criminal offence in the United States.

Panmure Liberum is authorised and regulated by the Financial Conduct Authority. Panmure Liberum is acting for the Selling Shareholder only in connection with the Placing and the Sale and no one else, and will not be responsible to anyone other than the Selling Shareholder for providing the protections offered to clients of Panmure Liberum nor for providing advice in relation to the ordinary shares or the Placing or the Sale, the contents of this announcement or any transaction, arrangement or other matter referred to in this announcement.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCUUASRVOUVAAR
Date   Source Headline
25th Jun 20267:00 amRNSInvestment in Autonomy Investment Partners
23rd Jun 20267:00 amRNSReceipt of Deferred Consideration
16th Jun 20267:01 amRNSFinal Dividend Declaration
16th Jun 20267:00 amRNSNotice of AGM
29th May 20267:00 amRNSDirector/PDMR Shareholding
27th May 20267:01 amRNSFinal Results for the Year to 31 January 2026
27th May 20267:00 amRNSDirectorate change
13th May 20267:00 amRNSTransaction in Own Shares
6th May 20267:00 amRNSNotice of Results and Investor Presentation
24th Apr 20265:50 pmRNSTransaction in Own Shares
20th Apr 20265:25 pmRNSSIP Awards, PDMR Dealings, Treasury Shares, TVR
16th Apr 20267:00 amRNSDeferred Consideration Receipt & Special Dividend
14th Apr 20267:00 amRNSTransaction in Own Shares
8th Apr 20267:00 amRNSTransaction in Own Shares
2nd Apr 20267:00 amRNSFollow-on equity purchase in Pantheon
31st Mar 20267:00 amRNSTransaction in Own Shares
30th Mar 20263:52 pmRNSDirector/PDMR Shareholding
26th Mar 20267:00 amRNSNew Share Buyback Programme
18th Mar 20267:00 amRNSNew Investment: Nine Edge Wealth Limited
18th Mar 20267:00 amRNSNew Investment: Ventura Risk Partners Holdings
17th Mar 20264:48 pmRNSSale of Interest in Amiga to Sodalis
11th Mar 20267:00 amRNSUpdate on Sodalis Capital Limited
24th Feb 20267:00 amRNSTrading Update
6th Feb 20267:00 amRNSPurchase of Own Shares and Total Voting Rights
5th Feb 202611:44 amRNSTransaction in Own Shares
21st Jan 20267:00 amRNSInterim Dividend Declaration
18th Dec 20257:00 amRNSTransaction in Own Shares & Total Voting Rights
15th Dec 20257:00 amRNSSpecial Dividend Declaration
11th Dec 20257:00 amRNSAppointment of Nominated Adviser and Joint Brokers
2nd Dec 20257:00 amRNSChange in Executive Directorship Roles
27th Nov 20256:17 pmRNSTransaction in Own Shares
27th Nov 20257:00 amRNSNew Investment: Sodalis Capital Limited
25th Nov 20254:55 pmRNSTransaction in Own Shares
24th Nov 20255:05 pmRNSTransaction in Own Shares
24th Nov 20257:00 amRNSTransaction in Own Shares
21st Nov 20257:00 amRNSTransaction in Own Shares
20th Nov 20257:00 amRNSTransaction in Own Shares
19th Nov 20257:57 amRNSTransaction in Own Shares
17th Nov 20257:00 amRNSTransaction in Own Shares
13th Nov 202512:38 pmRNS-RB.P. Marsh to present at MelloLondon
11th Nov 20255:08 pmRNSTransaction in Own Shares
7th Nov 20257:00 amRNSTransaction in Own Shares
6th Nov 20257:00 amRNSTransaction in Own Shares
5th Nov 20257:00 amRNSTransaction in Own Shares
4th Nov 20257:00 amRNSTransaction in Own Shares
30th Oct 20257:00 amRNSTransaction in Own Shares
28th Oct 20257:01 amRNSTransaction in Own Shares
28th Oct 20257:00 amRNSSale of Stewart Specialty Risk Underwriting
27th Oct 20257:00 amRNSTransaction in Own Shares
21st Oct 20257:00 amRNSHalf-year Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.